CD8A and neoplasm: To match that estimated rate, we repeatedly administered 500 ng doses of mCXCL10 solutions in PBS every other day over the 5 days of dosing Upon completion of the study, we observed significant tumor growth attenuation and a significant increase in CD8+ T‐cell trafficking in B16 melanoma flank tumors after a single dose of the hydrogels tethered to mCXCL10‐3azidoester, equivalent to the results observed in the soluble mCXCL10 condition that was administered multiple times (Figures 7b–d and S10).